This is unpublished
Hansa Study
Active Studies
Transplantation
Pinned
Principal Investigator
Nicolae Leca, MD
Funding Agency
Sponsor : Hansa Biopharma AB
Status
Active
Enrollment closed
Investigator
What is the Hansa Study?
This is a study of kidney function in highly sensitized (cPRA ≥99.90%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care. Imlifidase works by breaking down IgG antibodies, reducing the likelihood of the body rejecting the donor kidney.
What are the criteria for the study?
This clinical trial targets male and female patients aged 18-70 who are willing to comply with the protocol and participate in a planned 4-year extension trial. Signed informed consent must be obtained prior to any trial-related procedures.
WHO DO I CONTACT FOR MORE INFORMATION?
Research Coordinator
Nidhi Mehta
E: nidhim3@Nephrology.washington.edu